Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
EARLY_PHASE1
27 participants
INTERVENTIONAL
2010-02-01
2014-10-06
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Cannabinoids, Learning, and Memory
NCT02407808
Cannabinoids, Neural Synchrony, and Information Processing
NCT00708994
Effects of THC and CBD on Human Episodic Memory Function
NCT02291562
Behavioral Pharmacology of THC and D-limonene
NCT03609853
THC and Ketamine Effects in Humans: Relation to Neural Oscillations and Psychosis
NCT04199468
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Active Canabidiol and Active Delta-9-THC
Cannabidiol
Active Cannabidiol 5mg.
Delta-9-THC
Active Delta-9-THC (0.035mg/Kg) given intravenously over 20 minutes. The dose of THC that you may receive is a small dose and is roughly equivalent to smoking approximately one half to one whole marijuana cigarette, or "joint".
Placebo and Active Delta-9-THC
Delta-9-THC
Active Delta-9-THC (0.035mg/Kg) given intravenously over 20 minutes. The dose of THC that you may receive is a small dose and is roughly equivalent to smoking approximately one half to one whole marijuana cigarette, or "joint".
Placebo
Placebo (about a quarter spoon of alcohol with no CBD).
Active Cannabidiol and Placebo
Cannabidiol
Active Cannabidiol 5mg.
Placebo
Placebo (about a quarter spoon of alcohol with no THC) given intravenously over 20 minutes.
Placebo and Placebo
Placebo
Placebo (about a quarter spoon of alcohol with no CBD).
Placebo
Placebo (about a quarter spoon of alcohol with no THC) given intravenously over 20 minutes.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cannabidiol
Active Cannabidiol 5mg.
Delta-9-THC
Active Delta-9-THC (0.035mg/Kg) given intravenously over 20 minutes. The dose of THC that you may receive is a small dose and is roughly equivalent to smoking approximately one half to one whole marijuana cigarette, or "joint".
Placebo
Placebo (about a quarter spoon of alcohol with no CBD).
Placebo
Placebo (about a quarter spoon of alcohol with no THC) given intravenously over 20 minutes.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
55 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Yale University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Mohini Ranganathan
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mohini Ranganathan, M.D
Role: PRINCIPAL_INVESTIGATOR
Yale University Medical School
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
VA Connecticut Healthcare System
West Haven, Connecticut, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Ganesh S, Cortes-Briones J, Schnakenberg Martin AM, Skosnik PD, D'Souza DC, Ranganathan M. Delta-9-Tetrahydrocannabinol, Cannabidiol, and Acute Psychotomimetic States: A Balancing Act of the Principal Phyto-Cannabinoids on Human Brain and Behavior. Cannabis Cannabinoid Res. 2023 Oct;8(5):846-856. doi: 10.1089/can.2021.0166. Epub 2022 Mar 18.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1001006240
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.